Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

Modified transanal drainage tube to prevent anastomotic leaks after rectal cancer surgery

Official title: Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage After Low Anterior Resection in Patients With Rectal Cancer: A Randomized Clinical Trial(PALARC 02)

Run by Third Military Medical University · NCT07036588 · Data updated 2026-11-12

This trial tests whether placing a modified transanal drainage tube can reduce anastomotic leakage in adults having sphincter-preserving rectal cancer surgery.

More Anastomotic Leak trials

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment968 (estimated)
SponsorThird Military Medical University
Academic / other
Locations1 site (Yuzhong, Chongqing Municipality)
StatusRecruiting
StartedJuly 7, 2025
Main results expectedDecember 31, 2027
Study endsDecember 31, 2030
Registry record updatedAugust 24, 2026
Trial IDNCT07036588 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–80 years old with pathologically confirmed rectal adenocarcinoma whose lower tumor edge is ≤10 cm from the anal verge, ASA ≤3, and who are candidates for laparoscopic or robotic sphincter-preserving surgery.

Probably not a fit

Patients undergoing emergency surgery, those with bowel obstruction, multiple primary colorectal cancers, long-term immunosuppression or uncontrolled infection, pregnant or breastfeeding women, or those not eligible for sphincter-preserving surgery are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized interventional trial assigns patients undergoing laparoscopic or robotic sphincter-preserving rectal cancer surgery to either a modified transanal drainage tube that allows postoperative irrigation or to a non-modified approach. Randomization is computer-generated and surgeons are informed of group assignment only after completing the anastomosis to avoid influencing intraoperative decisions, with pelvic drains used in all cases. Surgical treatment follows total mesorectal excision principles with selective preservation of the left colic artery and selective diverting stoma based on intraoperative risk assessment. Primary outcomes include the incidence of anastomotic leakage, need for reoperation, and short-term postoperative recovery metrics.

Why it matters

Potential benefit: If successful, the modified tube could lower anastomotic leak rates, reduce reoperations and hospital stays, and improve short- and long-term outcomes after rectal cancer surgery.

How similar studies have gone: Prior research showed traditional transanal drainage tubes did not reliably prevent leaks, so the modified irrigatable TDT approach is relatively novel with limited prior evidence of benefit.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Rectal adenocarcinoma (confirmed by pathology);
* Tumor location: The lower edge is ≤10 cm from the anal verge;
* Age: ≥18 and ≤80 years old;
* ASA ≤3 ;
* After assessment, laparoscopic/robotic sphincter - preserving surgery for rectal cancer is feasible;
* T2 - 4N0 - 2M0\~T0 - 1N1 - 2M0 \& non- local recurrence;
* Signed informed consent form;
* Able to understand the risks of participating in the trial.

Exclusion Criteria:

* Emergency surgery;
* Presence of multiple primary colorectal cancers;
* History of long - term use of immunosuppressants or corticosteroids;
* Patients with severe mental illness or uncontrolled infection before surgery;
* Pregnant or breastfeeding women;
* Bowel obstruction before surgery;
* BMI ≥35.0

Where it's running

  • Army Medical Center (Daping Hospital)
    Yuzhong, Chongqing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.